+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Latanoprost on Blood-Retinal Barrier Permeability in Rabbits

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Purpose: To investigate the effect of latanoprost (LP) on the inward and outward permeability (P<sub>in</sub> and P<sub>out</sub>) of the blood-retinal barrier (BRB). Methods: Four New Zealand white rabbits received topical LP (0.005%) once daily for 3 weeks in one eye and phosphate-buffered saline (PBS) in the fellow eye (topical group). Five New Zealand white rabbits were injected intravitreously with LP (0.1 ml, 0.005%) in one eye and PBS (0.1 ml) in the fellow eye (injection group). In the injection group, vitreous fluorophotometry (VFP) to estimate the P<sub>in</sub> and differential vitreous fluorophotometry (DVF) to estimate the P<sub>out</sub> were performed 60 min after LP was injected. After the baseline measurements, VFP and DVF were performed 60 and 180 min after intravenous injection of sodium fluorescein, respectively. Fluorescein (F) and fluorescein monoglucuronide (FG) concentrations were obtained by DVF, and the F/FG ratio was calculated as an index of the P<sub>out</sub>. Results: In the topical group, there were no significant differences in the P<sub>in</sub> or F/FG ratio between the LP- and the PBS-treated eyes. In the injection group, the P<sub>in</sub> in the LP-treated eyes was significantly higher than in PBS-treated eyes (p < 0.05). There was no significant difference in the F/FG ratio between the two groups. Conclusion: Although we cannot exclude the effect of differences in species, the physiologic effect of LP, which increased the P<sub>in</sub>, was seen in experimental studies. Because antiglaucoma drugs are generally used over an extended period, further clinical studies of the effect of LP on the BRB should be performed in patients who have BRB breakdown, such as in uveitis, and in patients who are pseudophakic and aphakic.

          Related collections

          Most cited references 10

          • Record: found
          • Abstract: found
          • Article: not found

          Cystoid macular edema associated with latanoprost in aphakic and pseudophakic eyes.

          To describe four patients who developed cystoid macular edema shortly after onset of treatment with latanoprost. Retrospective review of medical records of patients with open-angle glaucoma who developed cystoid macular edema shortly after starting latanoprost. The use of topical latanoprost was temporally related to the development of cystoid macular edema in four patients (six eyes; two aphakic eyes and four pseudophakic eyes). Cystoid macular edema resolved in all patients after latanoprost was discontinued. Cystoid macular edema is a potential complication of latanoprost therapy. Further observations are needed to determine if the risk of cystoid macular edema is limited to or greatest in patients who are pseudophakic or aphakic.
            • Record: found
            • Abstract: found
            • Article: not found

            Latanoprost-associated cystoid macular edema.

            To report two cases in which cystoid macular edema developed after initiation of topical latanoprost for glaucoma.
              • Record: found
              • Abstract: not found
              • Article: not found

              Anion-sensitive ATPase in rabbit corneal endothelium and its relation to corneal hydration.


                Author and article information

                Ophthalmic Res
                Ophthalmic Research
                S. Karger AG
                October 2003
                22 August 2003
                : 35
                : 5
                : 276-280
                Department of Ophthalmology, Asahikawa Medical College, Asahikawa, Japan
                72150 Ophthalmic Res 2003;35:276–280
                © 2003 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                Page count
                Tables: 1, References: 48, Pages: 5
                Original Paper


                Comment on this article